Brief: Plus Therapeutics Announces Validation, Clinical Implementation Of CSF-01 Leptomeningeal Cancer Cell Diagnostic
25/03/2024 14:28
March 25 (Reuters) - Plus Therapeutics Inc PSTV.O :
* PLUS THERAPEUTICS ANNOUNCES VALIDATION & CLINICAL
IMPLEMENTATION
OF CSF-01 LEPTOMENINGEAL CANCER CELL DIAGNOSTIC
Source text for Eikon: ID:nGNX66ykB7
Further company coverage: PSTV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer